Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD

Longitudinal Natural History Protocol for PRKN- and PINK1-linked PD

Background:

Parkinson s disease is a neurologic disorder that affects movement. Its cause is unknown, and it usually begins later in life. Gene changes (PRKN and PINK1) can also cause rare types of Parkinson s disease that start at a young age. Researchers want to conduct a natural history study to learn more about how genes play a role in Parkinson s disease.

Objective:

To collect data and biological samples from people with different types of Parkinson s disease.

Eligibility:

People aged 18 to 80 years with either Parkinson s disease or PRKN- and PINK1-linked Parkinson s disease. Healthy volunteers are also needed.

Design:

Participants will have 6 clinic visits over 5 years. Each visit may take 1 to 3 days.

During each visit:

Participants will have a physical exam. The exam will be videotaped.

They will answer questions about their movement, thinking, mood, and sense of smell. The extent of any symptoms of Parkinson s disease will be evaluated: Participants movements may be assessed with a finger tapping test. They may be asked to scratch and sniff different scented strips to identify odors.

They will wear motion sensors on their arms, legs, chest, and back at the clinic. They will wear motion sensor devices on their wrists at home for 1 week.

Blood and urine samples will be collected.

Other tests are optional:

Magnetic resonance imaging (MRI) scan of the brain. Participants will lie on a table that slides into a tube.

Lumbar puncture (spinal tap). A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.

Muscle biopsy. A small sample of tissue will be taken from the leg.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Detaljerad beskrivning

Study Description:

This is a longitudinal, observational study that aims to assess progression of clinical features, imaging, and biologic markers of PD in study participants with and without manifest PD who are bi-allelic or mono-allelic carriers of pathogenic variants in the recessively inherited genes PRKN and PINK1 that represent prototypes of mitochondrial- associated PD.

Objectives:

Primary Objective: To characterize the natural history of motor symptoms in PRKN- and PINK1-linked PD.

Secondary Objectives: To comprehensively characterize other clinical features of PRKN- and PINK1-linked PD over time

Tertiary Objectives:

  • To characterize structural brain changes over time
  • To identify molecular signatures that differ between PRKN and PINK1-associated PD, non-manifesting mutation carriers, wildtype PD, and healthy controls.
  • To generate a repository of longitudinal data and samples for future studies aimed at developing targeted therapies.
  • To characterize in-home assessment of movements
  • To evaluate for mitochondrial changes in the muscle

Endpoints:

Primary Endpoint: Annual change in MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

Secondary Endpoints:

  • Annual change in MDS-UPDRS parts I, II, IV
  • Annual change in Montreal Cognitive Assessment (MoCA)
  • Annual change in Timed up and go (TUG)
  • Annual change in 10-meter walk
  • Annual change in 360 degree turn
  • Annual change in Unified Dyskinesia Rating Scale (UDysRS)
  • Annual change in University of Pennsylvania Smell Identification Test (UPSIT)
  • Annual change in REM-Sleep-Behavior Disorder Screening Questionnaire (RBD-SQ)
  • Annual change in Questionnaire for Impulsive-Compulsive Disorders (QUIP)
  • Annual change in Epworth Sleepiness Scale (ESS)
  • Annual change in Geriatric Depression Scale (GDS)
  • Annual change in State-Trait Anxiety Inventory (STAI)
  • Annual change in Scales for Outcomes in Parkinson s Disease - Autonomic Dysfunction (SCOPA AUT)
  • Annual change in 39-item Parkinson s Disease Questionnaire (PDQ-39)- quality of life measurement
  • Annual change in Schwab and England Activities of Daily Living (SE-ADL) scale
  • Annual change in Hoehn and Yahr scale assessment Tertiary endpoints:
  • Annual change of brain MRI measurement of overall brain, striatum and substantia nigra volumes
  • Annual change of brain MRI measurement of iron deposition
  • Annual change in studies from blood
  • Annual change in studies from CSF
  • Annual change in studies from urine
  • Annual change in Wearable Accelerometry data
  • Evidence of mitochondrial cytopathy on muscle biopsy

Studietyp

Observationell

Inskrivning (Beräknad)

70

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Maryland
      • Bethesda, Maryland, Förenta staterna, 20892
        • National Institutes of Health Clinical Center
        • Kontakt:
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • Telefonnummer: TTY dial 711 800-411-1222
          • E-post: ccopr@nih.gov

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

There will be a total of up to 50 male or female participants 18- 80 years of age and older in 5 cohorts. Target number of completers for each cohort are listed below: - PD mito-biallelic (PD participants carrying two pathogenic variants in PRKN or PINK1): up to 15 - PD mito-monoallelic (PD participants carrying one pathogenic mono-allelic variant in PRKN and/or PINK1): up to 10 - PD idiopathic: up to 5 - Non-manifesting mito (participants who carry one or two pathogenic variants in PRKN and/or PINK1 but do not have a diagnosis of PD): up to 15 - Healthy controls: up to 5

Beskrivning

  • INCLUSION CRITERIA:

To be eligible to participate in this study, an individual must meet all of the following criteria:

All participants:

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female between the ages of 18-80 years old
  • Ability of subject to understand and the willingness to sign an informed consent document
  • Ability of subject to travel to the NIH Clinical Center

Additional inclusion criteria for each cohort as below:

PD Mito - Biallelic:

  • Established clinical diagnosis of Parkinson's disease
  • Two Pathogenic or likely pathogenic variants in PRKN or PINK1

PD Mito - Monoallelic:

  • Established clinical diagnosis of Parkinson's disease
  • One Pathogenic or likely pathogenic variant in PRKN and/or PINK1

Idiopathic Parkinson's Disease (PD):

  • Established clinical diagnosis of Parkinson's disease
  • Etiology of PD is idiopathic/sporadic based on investigator determination

Non-manifesting mito:

  • One or two pathogenic or likely pathogenic variant in PRKN and/or PINK1
  • Lack of clinical diagnosis of Parkinson's disease
  • Lack of current or clinically significant neurological disorder (based on investigator determination)

Healthy Volunteer

-Lack of current or clinically significant neurological disorder (based on investigator determination)

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

All participants:

  • Symptomatic PD syndromes due to drugs (e.g., metoclopramide, flunarizine, neuroleptics), metabolic disorders (e.g., Wilson's disease hypothyroidism), encephalitis, brain lesion, atypical parkinsonism, other monogenic forms of PD (e.g., GBA1, LRRK2, SNCA, VPS35, CHCHD2, DJ1, ATP13A2) other genetic disorders that may cause parkinsonism (e.g., spinocerebellar ataxia, X-linked dystonia parkinsonism)
  • Pregnancy at time of study enrollment
  • Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment
  • Unwilling to allow samples or data to be shared with other researchers or institutions.
  • NIH staff or family members of study team members

Healthy Volunteer:

-Participants who become pregnant during the study will be withdrawn from further study procedures at the time pregnancy is identified.

Procedural Exclusions:

Subjects may still be enrolled if they cannot participate in certain procedures due to not meeting the inclusion requirements for that specific procedure. Subjects who meet exclusion criteria for procedures listed below may still undergo the procedure at a later time if the reason of exclusion is no longer present.

Brain MRI:

  • Contraindications to MRI such as a contraindicated non-removable metal device (i.e., pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry)
  • Pregnancy

Accelerometer:

-Non ambulatory

Lumbar puncture procedure:

  • PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  • INR greater than 1.4, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction
  • History of a bleeding disorder
  • Use of anticoagulants or antiplatelets
  • Pregnancy
  • History of headache requiring blood patch after a previous LP

Needle muscle biopsy:

  • PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  • INR greater than 1.4, thrombocytopenia (<70,000), or abnormal bleeding time or platelet dysfunction
  • History of a bleeding disorder
  • Use of anticoagulants or antiplatelets
  • Pregnancy

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Healthy controls
Lack of current or clinically significant neurological disorder (based on investigator determination).
Non-manifesting mito
participants who carry one or two pathogenic variants in PRKN and/or PINK1 but do not have a diagnosis of PD
PD idiopathic
PD participants with idiopathic PD
PD mito - monoallelic
Monoallelic: PD participants carrying one pathogenic mono-allelic variant in PRKN and/or PINK1
PD mito - biallelic
Biallelic: PD participants carrying two pathogenic variants in PRKN or PINK1

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Estimation of progression of motor symptoms across cohorts
Tidsram: When final patient completes their last visit
Measured by annual change in MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
When final patient completes their last visit

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Annual change in MDS-UPDRS parts I, II, IV
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Montreal Cognitive Assessment (MoCA)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Timed up and go (TUG)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 10-meter walk
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 360 degree turn
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Unified Dyskinesia Rating Scale (UDysRS)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in University of Pennsylvania Smell Identification Test (UPSIT)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in REM-Sleep-Behavior Disorder Screening Questionnaire (RBD-SQ)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Questionnaire for Impulsive-Compulsive Disorders (QUIP)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Epworth Sleepiness Scale (ESS)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Geriatric Depression Scale (GDS)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in State-Trait Anxiety Inventory (STAI)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA AUT)
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in 39-item Parkinson's Disease Questionnaire (PDQ-39) - quality of life measurement
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Schwab and England Activities of Daily Living (SE-ADL) scale
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit
Annual change in Hoehn and Yahr scale assessment
Tidsram: When final patient completes their last visit
Characterization of other clinical features of PRKN- and PINK1- linked PD over time
When final patient completes their last visit

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Debra J Ehrlich, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 oktober 2026

Primärt slutförande (Beräknad)

30 maj 2036

Avslutad studie (Beräknad)

30 maj 2036

Studieregistreringsdatum

Först inskickad

28 maj 2026

Först inskickad som uppfyllde QC-kriterierna

28 maj 2026

Första postat (Faktisk)

29 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 juni 2026

Senast verifierad

20 maj 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • 10002619
  • 002619-N

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på PARKINSON DIS

Prenumerera